Paul Peter Tak serves as Executive at Candel Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Paul Peter Tak has executed 8 insider transactions totaling $496.9K, demonstrating a bearish approach to their equity position. Their most recent transaction on Jul 17, 2024 involved selling 22,528 shares valued at $145.8K.
Paul Peter Tak currently holds 330,735 shares of Candel Therapeutics, Inc. (CADL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Paul Peter Tak has been a net seller of CADL stock. They have purchased $230.0K and sold $266.9K worth of shares.
Paul Peter Tak's most recent insider trade was on Jul 17, 2024, when they sold 22,528 shares at $6.47 per share.
Get notified when new Form 4 filings are submitted
| $5.97 |
| Discretionary |
| Nov 28, 2023 | CADL | $39.1K | Payment | 43,443 | $0.90 | Discretionary |
| Nov 26, 2023 | CADL | $0 | Award | 180,108 | $N/A | Discretionary |
| Dec 9, 2022 | CADL | $24.8K | Purchase | 12,935 | $1.92 | Discretionary |
| Dec 8, 2022 | CADL | $5.2K | Purchase | 3,050 | $1.70 | Discretionary |
| Nov 28, 2022 | CADL | $0 | Award | 195,906 | $N/A | Discretionary |
| Jul 29, 2021 | CADL | $200.0K | Purchase | 25,000 | $8.00 | Discretionary |